Last update 22 Dec 2024
CX1440
Last update 22 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms CX 1440, CX-1440, OB1440 |
Target |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors) |
Therapeutic Areas |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
5
Clinical Trials associated with CX1440评价CX1440胶囊在治疗持续性或慢性原发免疫性血小板减少症(ITP)成人患者中的安全性和疗效的Ib/II期临床研究
[Translation] A Phase Ib/II clinical study to evaluate the safety and efficacy of CX1440 capsules in the treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP)
Efficacy and safety of CX1440 capsules in the treatment of persistent or chronic primary immune thrombocytopenia: a multicenter, randomized, open-label, phase 1/2 study.
健康受试者单次、多次口服CX1440胶囊的安全性、耐受性与药代、药效动力学及食物对CX1440胶囊药代动力学影响的Ⅰ期临床研究
[Translation] Phase I clinical study on the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral administration of CX1440 capsules in healthy subjects and the effect of food on the pharmacokinetics of CX1440 capsules
100 Clinical Results associated with CX1440
Login to view more data
100 Translational Medicine associated with CX1440
Login to view more data
100 Patents (Medical) associated with CX1440
Login to view more data
100 Deals associated with CX1440
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Purpura, Thrombocytopenic, Idiopathic | Phase 2 | CN | 03 Feb 2023 | |
| B-Cell Malignant Neoplasm | Phase 1 | CN | 16 Sep 2020 | |
| B-Cell Malignant Neoplasm | Phase 1 | CN | 16 Sep 2020 | |
| Systemic Lupus Erythematosus | IND Approval | CN | 08 Nov 2022 | |
| Urticaria | IND Approval | CN | 16 Sep 2022 | |
| Chronic graft-versus-host disease | IND Approval | CN | 01 Sep 2022 | |
| Multiple Sclerosis, Chronic Progressive | IND Approval | CN | 01 Nov 2021 | |
| Multiple Sclerosis, Relapsing-Remitting | IND Approval | CN | 01 Nov 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free